Pfizer Aktie
22,20
EUR
-0,49
EUR
-2,14
%
24,48
USD
-0,20
USD
-0,79
%
Kursziele der Pfizer-Aktie in USD
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Pfizer-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 28,00 USD | +14,40% | 07.03.2025 | |
| DZ BANK | - | - | 05.02.2025 | |
| Goldman Sachs Group Inc. | 32,00 USD | +30,75% | 05.02.2025 | |
| UBS AG | 28,00 USD | +14,40% | 05.02.2025 | |
| JP Morgan Chase & Co. | 30,00 USD | +22,57% | 05.02.2025 | |
| Jefferies & Company Inc. | 33,00 USD | +34,83% | 04.02.2025 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 139,66 GBP | +22,59% |
| Bayer | 1 | 8 | 0 | 24,88 EUR | +16,94% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +63,38% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,62 GBP | +13,41% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 180,57 EUR | +48,25% |
| MorphoSys | 0 | 1 | 0 | 68,00 EUR | - |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,12 CHF | +1,87% |
| Perrigo Company | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 3 | 0 | 30,20 USD | +23,37% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 115,50 EUR | +16,05% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |